

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Protocol for a pilot randomised controlled trial: A brief self-compassion intervention for adolescents with type 1 diabetes and disordered eating

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034452
Article Type:	Protocol
Date Submitted by the Author:	20-Sep-2019
Complete List of Authors:	Boggiss, Anna; The University of Auckland Faculty of Medical and Health Sciences, Psychological Medicine Consedine, Nathan; The University of Auckland Faculty of Medical and Health Sciences, Psychological Medicine Jefferies, Craig; Starship Children's Health, Auckland City Hospital Bluth, Karen; University of North Carolina at Chapel Hill, Psychiatry Hofman, Paul; The University of Auckland Liggins Institute Serlachius, Anna; The University of Auckland Faculty of Medical and Health Sciences, Psychological Medicine
Keywords:	self-compassion, adolescence, disordered eating, type 1 diabetes, psychosocial interventions, clinically usable interventions

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Protocol for a pilot randomised controlled trial: A brief self-compassion intervention**  
4  
5 **for adolescents with type 1 diabetes and disordered eating**  
6  
7  
8  
9

10 Anna L. Boggiss, PGDip<sup>1</sup>, Nathan S. Consedine, PhD<sup>1</sup>, Craig Jefferies, MD<sup>2</sup>, Karen Bluth,  
11 PhD<sup>3</sup>, Paul L. Hofman, MD<sup>4</sup>, and Anna S. Serlachius, PhD<sup>1</sup>  
12  
13

14 <sup>1</sup>Department of Psychological Medicine, Faculty of Medical and Health Sciences, University  
15 of Auckland, Auckland, New Zealand  
16  
17

18 <sup>2</sup>Starship Children's Health, Auckland City Hospital, Auckland, New Zealand  
19  
20

21 <sup>3</sup>Department of Psychiatry, University of North Carolina, Chapel Hill, United States of  
22 America  
23  
24

25 <sup>4</sup>Liggins Institute, University of Auckland, Auckland, New Zealand  
26  
27

28 Corresponding author: Anna Boggiss, Department of Psychological Medicine, University of  
29 Auckland, Auckland, New Zealand. Email: abog579@aucklanduni.ac.nz. Phone number +64  
30 9 923 3073.  
31  
32  
33  
34  
35  
36

37 *Keywords: self-compassion, adolescence, disordered eating, type 1 diabetes,*  
38 *psychosocial interventions, clinically usable interventions*  
39  
40

41  
42 Tables/Figures: 1 table and 1 figure  
43

44  
45 Word count: 3,656  
46

47 Dates of the study: recruitment started 24<sup>th</sup> May 2019, recruitment estimated to be complete  
48 by early November 2019, data collection estimated to be complete by late January 2020  
49  
50

51 Issue date: 20 Sep 2019  
52

53 Protocol amendment number: 01  
54

55 Authors: AB, NS, PH, KB, AS  
56  
57  
58  
59  
60

## Abstract

**Introduction:** Adolescents with type 1 diabetes are at a higher risk of developing psychiatric disorders, particularly eating disorders, compared to their healthy peers. In turn, this increases the risk for sub-optimal glycaemic control and life-threatening diabetes-related complications. Despite these increased risks, standard diabetes care does not routinely provide psychological support to help prevent or reduce mental health risks. There is an urgent need to develop ‘clinically usable’ psychosocial interventions, that are acceptable to patients and can be realistically integrated into clinical care. This study aims to examine the feasibility and acceptability of a brief self-compassion intervention for adolescents with type 1 diabetes and disordered eating behaviour.

**Methods and analysis:** This pilot randomised controlled trial (RCT) will examine the effectiveness of a brief self-compassion intervention, compared to a waitlist control group. Participants aged 12-16 years will be recruited from three diabetes outpatient clinics in Auckland, New Zealand. The brief self-compassion intervention is adapted from the standardised ‘Making Friends with Yourself’ (MFY) intervention and will be delivered in a group format over two sessions. As well as examining feasibility and acceptability through the flow of participants through the study and qualitative questions, we will assess changes to disordered eating behaviour (primary outcome), self-care behaviours, diabetes-related distress, self-compassion, stress and glycaemic control (secondary outcomes). Such data will be used to calculate the required sample size for a fully powered RCT.

**Ethics and dissemination:** The current trial has received ethics approval from the Health and Disability Ethics Committee (HDEC; research project number A+8467). Study results will be disseminated through peer-reviewed journals and conferences.

**Trial registration number:** ANZCTR (12619000541101).

**Strengths and Limitations:**

- There is an urgent need to develop ‘clinically usable’ interventions in diabetes care
- Self-compassion may offer an effective method to improve psychological health and self-management among adolescents with type 1 diabetes
- The pilot randomised controlled trial will evaluate the feasibility, acceptability and short-term efficacy of the brief self-compassion intervention in 28 teenagers with type 1 diabetes
- The study will inform a larger, multi-centred, fully-powered, randomised controlled trial, with the aim of implementing an effective and clinically usable intervention into standard diabetes care

## Introduction

This protocol paper describes a pilot RCT designed to evaluate the feasibility, acceptability, and short-term efficacy of a brief self-compassion intervention for adolescents with type 1 diabetes (T1D) and disordered eating behaviours. Adolescents with T1D face the dual challenge of learning how to manage their chronic condition while concurrently dealing with what can be normatively difficult developmental changes. Maintaining optimal self-management of T1D requires adherence to a complicated routine of daily self-administration of insulin and monitoring diet, energy expenditure and blood glucose levels (1). Adolescents must learn how to make these complex routines flexible enough to implement into their daily life including school, hobbies and other activities (2). Unsurprisingly, diabetes self-management tends to deteriorate during adolescence, with adolescents showing sub-optimal glycaemic control and higher rates of complications compared to adults or younger children (3).

Adolescents with T1D also show much greater rates of psychological disorders, especially eating disorders, than their healthy peers (4, 5). In a recent national Australian study of adolescents with T1D, 50% of female and 18% of male adolescents scored over the cut-off for disordered eating behaviour (6). Eating disorders have also been shown to be twice as common in adolescent females with T1D compared to their healthy peers (7) and rates of disordered eating in adolescents with T1D are rising (8, 9). Given that behaviours such as insulin omission and purging are associated with increases in diabetes-related complications (6, 10), this is concerning. Poor psychological health, including disordered eating, has the potential to make daily self-management decisions even more challenging and has known associations with lower rates of glucose testing and insulin adherence (11), poorer glycaemic control (12) and more frequent hospitalisations and complications (13). Therefore,

1  
2  
3 prioritising psychological health and wellbeing is an essential component of successful  
4  
5 diabetes care and may be even more relevant during adolescence.  
6

7  
8 Despite the high prevalence of mental health disorders among adolescents with T1D,  
9  
10 treatment options are limited. Current interventions to target psychological issues include  
11  
12 psychopharmacology (such as antidepressants) and psychosocial interventions. Research has  
13  
14 shown that individual and group-based interventions focused on improving family  
15  
16 relationships, stress management, and coping skills can improve adherence, glycaemic  
17  
18 control and quality of life (14). However, such interventions are rarely incorporated into  
19  
20 standard diabetes care due to funding constraints and a lack of therapist availability (15, 16),  
21  
22 as well as the logistical issues associated with family therapies. Furthermore, only one study  
23  
24 has examined the use of an intervention specifically targeting disordered eating behaviour in  
25  
26 adolescents with T1D (17). There is thus a strong need to develop interventions to treat  
27  
28 psychological distress, especially disordered eating behaviour, that are acceptable to  
29  
30 adolescents with T1D and can be realistically incorporated into routine clinical care.  
31  
32  
33

34  
35 Self-compassion is an emerging approach which may offer an effective method to  
36  
37 improve psychological health and self-management among adolescents with T1D. Self-  
38  
39 compassion appears highly relevant to the self-criticisms that commonly arise following  
40  
41 difficulty adhering to complex self-management regimens. At its core, self-compassion is  
42  
43 characterised by: (1) being aware of one's moment to moment experiences with a sense of  
44  
45 emotional balance and non-judgement (mindfulness), (2) acknowledging that suffering and  
46  
47 imperfection are part of being human (common humanity), and (3) taking an active role in  
48  
49 being caring and understanding toward oneself (self-kindness) (18). Lower self-compassion  
50  
51 has been closely linked to greater depression and anxiety (19), including in adults with  
52  
53 diabetes (20, 21), while higher self-compassion is associated with less rumination, self-  
54  
55 criticism, perfectionism, and fear of failure (18, 22). Self-compassion has demonstrated  
56  
57  
58  
59  
60



1  
2  
3 benefits for those with chronic illnesses (including inflammatory bowel disease and arthritis),  
4 such as improved self-management and coping (23). Most recently, a standardised 8-week  
5 self-compassion programme for adolescents, ‘Making Friends with Yourself’ (MFY),  
6 adapted from the Mindful Self-Compassion (MSC) Program for adults (24), showed  
7 significant improvements in self-compassion, life satisfaction and depression, compared to a  
8 waitlist control group, in healthy adolescents (23). Mindfulness, social connectedness,  
9 anxiety, stress, resilience, curiosity and gratitude have also been shown to increase  
10 throughout the MFY programme (25, 26).  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

21 To date, MFY has not been trialled in adolescents with diabetes or any other chronic  
22 illness. However, a recent RCT compared the 8-week MSC Programme for adults with  
23 diabetes to a waitlist control group (21). Researchers found increased self-compassion was  
24 associated with reductions in diabetes-related distress, depression, and improvements in  
25 glycaemic control, both at post-intervention and at the 3-month follow-up compared to the  
26 waitlist control group.  
27  
28  
29  
30  
31  
32  
33  
34

35 Considering the vital role psychological health plays in diabetes-related outcomes  
36 (27) and the conceptual fit between the purpose of self-compassion training and the issues  
37 confronting adolescents with T1D, we developed a brief (2-session) self-compassion  
38 intervention targeted to adolescents with T1D and disordered eating behaviour. The current  
39 study will examine the programme’s feasibility and acceptability for adolescents with T1D  
40 and provide estimates of change in psychological and physical health outcomes. It is  
41 hypothesised that the brief self-compassion intervention will improve disordered eating  
42 behaviours, self-care behaviours, diabetes-related distress, self-compassion, stress and  
43 glycaemic control, compared to the waitlist control group at post-intervention.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

## 55 **Methods and analysis**

### 56 **Design overview**

1  
2  
3 The study is a pilot RCT of a brief self-compassion intervention (treatment group),  
4 compared to a waitlist control group, in 28 adolescents with T1D. The study will be  
5 conducted in accordance to the CONSORT guidelines (28) and has been prospectively  
6 registered in the Australian New Zealand Clinical Trials Registry (ANZCTR  
7 12619000541101). The SPIRIT recommendations were adhered to in reporting the protocol  
8 (29).  
9  
10  
11  
12  
13  
14  
15

### 16 **Participants**

17  
18 Participants in the study are adolescents with T1D who are currently being recruited  
19 from three paediatric and adolescent diabetes clinics in Auckland, New Zealand. Adolescents  
20 are eligible for inclusion in the study if they meet the following criteria: (1) are aged 12 to 16  
21 years, (2) diagnosed with T1D more than 6 months ago at time of recruitment and (3)  
22 demonstrate moderate to high instances of disordered eating behaviour on the Diabetes  
23 Eating Problem Survey Revised (DEPS-R) (30) screening tool. A moderate to high  
24 disordered eating behaviour cut-off score was chosen to allow more room to detect changes  
25 and to offer the interventions to those at the highest risk. Exclusion criteria includes: (1) non-  
26 English speaking adolescents, (2) adolescents with developmental disorders (e.g. Autism  
27 Spectrum Disorder) and (3) adolescents diagnosed with a serious mental disorder requiring  
28 ongoing treatment (e.g., psychosis). See Figure 1 for an overview of the proposed flow of  
29 participants through the study.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

### 46 **Sample size calculation**

47  
48 Based on other studies suggesting the prevalence of disordered eating of 27% for boys  
49 and 42% for girls in T1D (31), we estimated that we would need to screen approximately 50  
50 adolescents to enroll at least 20 adolescents (who score over the cut-off on the DEPS-R) for  
51 the pilot study. We will use the observed changes in psychological outcomes (e.g., DEPS-R)  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 and physical health outcomes to calculate the required sample size for a subsequent fully  
4  
5 powered RCT.  
6

### 7 8 **Intervention development**

9  
10 The brief self-compassion intervention was adapted from the 8-week MFY  
11  
12 programme (25), in consultation with Karen Bluth and five other trained MFY and MSC  
13  
14 teachers. Components from the MFY programme were chosen for the brief adaption because  
15  
16 they are: (1) foundational exercises covering the basics of mindfulness and self-compassion  
17  
18 and (2) address body image concerns and feelings of isolation, which have been highlighted  
19  
20 in the literature to be relevant to adolescents with T1D (32). These components included  
21  
22 group exercises and discussions, topics, art activities, meditations and individual reflection  
23  
24 exercises (see Table 1).  
25  
26  
27

### 28 **Brief self-compassion intervention**

29  
30 The brief self-compassion intervention will involve two 2-hour sessions conducted at  
31  
32 the University of Auckland. The intervention sessions will be facilitated by the first author  
33  
34 (A.B), a trained MFY teacher.  
35  
36

37  
38 As summarised in Table 1, Session 1 will focus on giving participants an  
39  
40 understanding of mindfulness through several tangible activities including a mindful  
41  
42 movement activity, group discussions and a mindful activity using a stone or shell.  
43  
44 Psychoeducation around adolescent brain development and emotion regulation systems (33)  
45  
46 will be taught to help to establish the reasons why mindfulness and self-compassion can help  
47  
48 with managing stress, especially in adolescence. Regarding self-compassion, the 'How  
49  
50 Would I Treat a Friend' exercise offers an interactive method of explaining self-compassion  
51  
52 before practicing the self-compassion coping skills of 'Comforting Gesture' (i.e. 'Soothing  
53  
54 Touch') and the 'Three Steps of Self-Compassion' (i.e. 'A Moment for Me'). The 'How  
55  
56 Would I Treat a Friend' exercise shows adolescents that they often treat themselves much  
57  
58  
59  
60

1  
2  
3 more harshly than they treat their friends through exploring their reactions to how they would  
4 treat themselves versus their friends in difficult situations, such as receiving a bad mark on an  
5 important test. Finding a 'Comforting Gesture' (such as holding your hands over your heart  
6 or stomach), involves practicing applying self-compassion to soothe and regulate emotions  
7 during stressful situations in one's life. The 'Three Steps of Self-Compassion' involves  
8 applying the three elements of self-compassion (mindfulness, common humanity and self-  
9 kindness) to cope with difficult emotions.  
10  
11  
12  
13  
14  
15  
16  
17  
18

19 Session 2 is focused on developing coping skills to deal with body image concerns  
20 and feelings of isolation. Opening with a loving-kindness meditation will provide a reminder  
21 of the concept of self-compassion and the 'Comforting Gesture' tool from Session 1 before  
22 summarising the content taught in the last session. Self-esteem versus self-compassion and  
23 the cost of social comparison is then discussed to help teens understand how comparing  
24 themselves to others can create suffering and to allow them to practice using the coping skills  
25 taught in Session 1 when they experience feelings of inadequacy. The 'Crossing the Line'  
26 group activity then emphasises the common humanity element of self-compassion by asking  
27 adolescents to cross a line of string if they have experienced certain feelings or situations,  
28 such as feelings of isolation, been bullied or having compared themselves to their friends or  
29 an image in the media. Adolescents will then practice a compassionate body scan meditation  
30 and writing themselves a compassionate letter as further skills to use surrounding body image  
31 concerns.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

49 Handbooks will be given to participants to review topics and outline the coping skills  
50 taught in the sessions, with examples of situations where it may be helpful to use them.  
51 Recordings of the meditations used in the sessions will also be emailed to the participant's  
52 parent/ caregiver and the participant.  
53  
54  
55  
56  
57

## 58 **Study procedure**

59  
60

1  
2  
3 The study started recruitment on the 24<sup>th</sup> of May 2019 and is estimated to finish in  
4 late October 2019. Figure 1 depicts the flow of participants through the trial. Eligible families  
5 will be invited by diabetes nurse educators at their Paediatric Diabetes Service clinic  
6 appointments to participate in a study investigating body image concerns in adolescents with  
7 T1D. Interested participants will be referred to the first author (A.B), who will verbally  
8 explain the study to interested families. Once consent/ assent is given, the adolescents will  
9 complete the DEPS-R screening tool. Participants who score over the cut-off score for  
10 moderate disordered eating behaviour, will then be randomised to either the treatment group  
11 or a waitlist control group (who will receive the intervention after the treatment group has  
12 completed post-intervention measures) on a 1:1 basis. Randomisation will occur via sealed  
13 envelopes labelled with sequential study numbers, prepared by a biostatistician independent  
14 of the study.

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31 After randomisation, participants will also complete standardised questionnaires  
32 measuring self-care behaviours, diabetes-related distress, self-compassion and stress in clinic  
33 or online. After completing the intervention, participants will be given the same  
34 questionnaires as well as open-ended questions to assess the acceptability and feasibility of  
35 the programme. Participants in the waitlist control will then start the intervention.

### 36 37 38 39 40 41 42 **Outcome measures**

43  
44  
45 The primary goal of this pilot study is to determine the feasibility and acceptability of  
46 the brief self-compassion intervention in the service of designing a larger, multi-centred,  
47 powered study. This will be assessed by evaluating whether adolescents with T1D are willing  
48 to participate in the intervention (i.e. recruitment and uptake), reasons for not wanting to  
49 participate, the acceptability of the delivered intervention (assessed via qualitative questions),  
50 study attrition rate and the suitability of the outcome measures. Qualitative data, through  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 questionnaires at post-intervention, will also be used to refine the intervention content and  
4  
5 comment on strengths and weaknesses of the program.  
6  
7

8 In addition, the following psychological and physical health outcomes will be  
9  
10 assessed to give preliminary estimates of the study's efficacy and to estimate the sample size  
11  
12 needed for a fully-powered RCT:  
13

- 14  
15 1. Disordered eating behaviour as measured by the Diabetes Eating Problem Survey  
16  
17 Revised (DEPS-R) (30). The DEPS-R is a 16-item diabetes-specific self-report  
18  
19 measure of disordered eating. Participants are asked how true each item is for  
20  
21 them (e.g., 'I feel fat when I take all of my insulin') on a 6-point Likert scale  
22  
23 (0=never to 6=always), with items summed to produce a total score. The scale has  
24  
25 demonstrated good reliability ( $\alpha=0.86-0.91$ ) and validity in adolescents with  
26  
27 diabetes samples (30, 34, 35). For the current study, the moderate disordered  
28  
29 eating cut-off ( $\geq 10$ ) for inclusion in the study will be used. DEPS-R results for all  
30  
31 adolescents screened for eligibility will be reported to give an indication of  
32  
33 prevalence of moderate disordered eating behaviour in the Pediatric Diabetes  
34  
35 clinics.  
36  
37  
38  
39
- 40  
41 2. Self-care behaviours as measured by the Self Care Inventory-Revised Version  
42  
43 (SCI-R) (36). The SCI-R is a 15-item questionnaire which assesses how often  
44  
45 diabetes self-care behaviours have been adhered to over the past one to two  
46  
47 months on a 5-point Likert scale (1=never to 5=always). The self-care behaviours  
48  
49 assessed include the main components of the type 1 diabetes self-management  
50  
51 routine such as monitoring and recording glucose levels, administering and  
52  
53 adjusting insulin and regulating meals and exercise. Items will be averaged and  
54  
55 converted to a 0-100-point scale to produce a total score, with higher values  
56  
57  
58  
59  
60

1  
2  
3 representing better self-care. The scale has shown good reliability ( $\alpha=0.77-0.78$ )  
4 and validity (37, 38).  
5  
6

- 7  
8 3. Diabetes-related distress as measured by Problem Areas in Diabetes Survey  
9  
10 (PAID) (39). The 20-item questionnaire lists common negative emotions related  
11 to living with diabetes such as, 'feeling alone with diabetes', and 'worrying about  
12 the future and the possibility of serious complications'. The 20-items are  
13 measured on a 6-point Likert scale (1=not a problem to 6=a serious problem),  
14 with items averaged to produce a total score. The scale demonstrates good  
15 reliability ( $\alpha=0.93$ ) and validity (40).  
16  
17 4. Self-compassion as measured by the Self-Compassion Scale, short form (SCS-SF)  
18 (41). The 12 items are measured on a 5-point Likert scale (1=almost never to  
19 5=almost always), with items averaged to create a total score. Example items  
20 include: 'when I fail at something important to me I become consumed by feelings  
21 of inadequacy' and 'when I'm feeling down I tend to obsess and fixate on  
22 everything that's wrong'. Reliability for this scale is good with a Cronbach alpha  
23 of  $\alpha = 0.77-.79$  (25, 26) in adolescent samples. Strong predictive, convergent and  
24 discriminant validity has also been demonstrated (42, 43).  
25  
26 5. Stress as measured by the Perceived Stress Scale (PSS) (44). The questionnaire  
27 assesses feelings of stress, hassles and coping during the past month. For example,  
28 'in the last month, how often have you felt that you were unable to control the  
29 important things in your life?'. The 14-items are measured on a 5-point Likert  
30 scale (0=never to 4=very often), with the score of each item combined to produce  
31 a total score. The scale has been shown to associate with glycaemic control (45)  
32 and demonstrates good reliability ( $\alpha=0.75-.88$ ) and validity (46).  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 6. Glycaemic control as measured by Glycosylated haemoglobin (HbA<sub>1C</sub>). HbA<sub>1C</sub> is  
4 a blood test collected during routine outpatient appointments (which occur every  
5 3-4 months), which is a reliable measure of blood glucose control over a period of  
6 3-4 months. HbA<sub>1C</sub> is measured in millimoles per mol (mmol/mol), with lower  
7 values indicating better glycaemic control (47). HbA<sub>1C</sub> ranges from 31 to 108  
8 mmol/mol, with the ideal target for all child and adolescent age groups being  
9 below 58 mmol/mol (1). HbA<sub>1C</sub> levels will be accessed from clinical records at  
10 baseline and post-intervention (window of 12-16 weeks after baseline).  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

### 22 **Data analysis plan**

23  
24 Descriptive statistics will be reported for proportion of adolescents who were  
25 screened and who scored over the cut-off for the DEPS-R, rates of disordered eating across  
26 all adolescents screened, number of adolescents who attended the sessions, and number of  
27 adolescents who dropped out of the study. Data will be tested for violations of statistical  
28 assumptions. Means, standard deviations and 95% confidence intervals will be reported with  
29 the analyses. An independent samples t-tests will be conducted at post-intervention (see time  
30 2, Figure 1) to test our hypothesis for differences between the intervention group and waitlist  
31 control group in disordered eating behaviour, diabetes-related distress, stress, self-care  
32 behaviours and self-compassion. An independent samples t-test will also be conducted at the  
33 12-week follow-up to assess any possible differences between groups for glycaemic control.  
34  
35 In addition, to increase sample size and statistical power, an exploratory analysis will  
36 combine post-intervention data from participants in the treatment group (at time 2) and  
37 participants in the waitlist control group (at time 3) to examine within and between group  
38 changes from baseline, using paired samples t-tests. An intention to treat analysis is planned.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

### 56 **Patient and Public Involvement**



1  
2  
3 Patients, carers and members of the public were not involved in the study design  
4  
5 phases of the current study. However, during the recruitment process patients who CHOOSE  
6  
7 not to participate will be asked to assess whether the time commitment or required travel was  
8  
9 a reason for not choosing to participate, when possible. In addition, patients who are  
10  
11 participants PARTICIPATE in the sessions will also provide qualitative feedback on the  
12  
13 burden of participating, the recruitment process and the format and content of the sessions to  
14  
15 inform the future RCT. Regarding dissemination of results, during recruitment we ask  
16  
17 patients whether they consent to the findings being disseminated via peer reviewed journal  
18  
19 articles and conferences. We also ask whether they would like to be informed of the results at  
20  
21 the end of the study and how (e.g. email/post). Patients who agree to being informed of the  
22  
23 study results are sent a letter with the key findings and any publications arising from the  
24  
25 study. In some cases, patients may also be invited to a departmental presentation of the study  
26  
27 findings.  
28  
29  
30  
31  
32

### 33 **Ethics and dissemination**

34  
35 The study was approved by the Health and Disability Ethics Committee (HDEC;  
36  
37 research project number A+8467). Due to screening for and only including adolescents with  
38  
39 disordered eating behaviour, it was recommended to include a waitlist control group (rather  
40  
41 than a standard care control group) in order to offer all eligible participants the intervention.  
42  
43 Participants who report significant psychological concerns, such as self-harm, or issues  
44  
45 relating to their diabetes that fall outside of the scope of the intervention, such as complex  
46  
47 self-management concerns, will be referred to the diabetes team psychologist. The paediatric  
48  
49 and adolescent diabetes team (including endocrinologists, diabetes nurse educators, dieticians  
50  
51 and a psychologist) will provide study support throughout the trial, including monitoring any  
52  
53 adverse events. Study results will be disseminated through peer-reviewed journals, a doctoral  
54  
55 thesis, and conference presentations.  
56  
57  
58  
59  
60

## Discussion

To our knowledge, the current study will be the first to assess the acceptability of self-compassion intervention for adolescents with T1D and examine the feasibility of a brief adaptation of the MFY programme. The intervention addresses the rising concern of disordered eating in adolescents with T1D (8, 9), building on the sparse literature in this area (17). The intervention will aim to teach adolescents evidence-based mindfulness and self-compassion skills to help them cope with stress, difficult emotions, self-management obstacles, and body image concerns and to determine whether self-compassion is a feasible and acceptable approach. As the prevalence and impact of these psychological concerns in adolescents with T1D is a current obstacle in diabetes care, the study will help determine whether self-compassion is a feasible and acceptable approach.

The novelty of testing self-compassion for adolescents with T1D and the brief format of the intervention are key strengths of this study. Firstly, although self-compassion has previously demonstrated efficacy in adults with diabetes (21) we believe it may be even more beneficial for adolescents with T1D. Adolescence is a period of vulnerability with an increased risk for self-criticism, poor self-esteem, and body image concerns (48). In adolescents with T1D these concerns are exacerbated by difficult self-management routines and parental conflict surrounding their diabetes-care (49), as well as increased risk of psychological distress and feelings of isolation (32). Self-compassion may encourage adolescents to be more accepting and kind to themselves when facing these issues, without engaging in problematic or counterproductive self-criticism. The common humanity aspect of self-compassion is likely to help validate feelings that emerge from any struggles they are experiencing, such as feelings of isolation, feeling less than, stress and sadness, as normal and common to all teens.

1  
2  
3 An adapted version of the ‘Making Friends with Yourself’ programme to a brief (2-  
4 session format) was chosen to address the lack of of ‘clinically usable’ interventions in  
5 diabetes care. Although it is widely acknowledged that psychological care is a key  
6 component of improving health outcomes in diabetes (16, 27), the integration of psychosocial  
7 care into routine diabetes care remains lacking. Despite the growing literature demonstrating  
8 the efficacy of psychosocial interventions for improving psychological outcomes in T1D,  
9 interventions are rarely designed with the intention of being ‘clinically usable’ and in a  
10 format that could potentially be adopted into standard care.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

21 Altogether, our aim is to examine the feasibility and acceptability of a brief self-  
22 compassion intervention, as well as provide estimates of short-term efficacy. If the brief self-  
23 compassion intervention is found to be feasible and acceptable to adolescents, future plans  
24 include conducting a fully powered RCT to examine the long-term efficacy of the  
25 intervention, with the intention of developing a clinically usable psychosocial intervention for  
26 youth with both T1D and disordered eating behaviours.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Authors contributions:** A.B, P.H and A.S came up with the conception and design of the  
4 study. A.B will be recruiting participants and conducting the program sessions. K.B provided  
5 training and consultation during the program development phase and will provide A.B with  
6 supervision throughout the sessions. A.B. and A.S. wrote the manuscript. N.S., P.H and K.B  
7 reviewed and edited the manuscript.  
8  
9  
10  
11  
12  
13  
14  
15  
16

17 **Funding statement:** This research received no specific grant from any funding agency in the  
18 public, commercial or not-for-profit sectors.  
19  
20  
21  
22  
23

24 **Competing interests statement:** The authors declare that they have no conflicts of interest.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Association AD. Standards of medical care in diabetes—2017 abridged for primary care providers. *Clinical diabetes: a publication of the American Diabetes Association*. 2017;35(1):5.
2. Chiang JL, Kirkman MS, Laffel LM, Peters AL. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. *Diabetes care*. 2014;37(7):2034-54.
3. Moore SM, Hackworth NJ, Hamilton VE, Northam EP, Cameron FJ. Adolescents with type 1 diabetes: parental perceptions of child health and family functioning and their relationship to adolescent metabolic control. *Health and quality of life outcomes*. 2013;11(1):50.
4. Reynolds KA, Helgeson VS. Children with diabetes compared to peers: depressed? Distressed? A meta-analytic review. *Annals of Behavioral Medicine*. 2011;42(1):29-41.
5. Young V, Eiser C, Johnson B, Brierley S, Epton T, Elliott J, et al. Eating problems in adolescents with Type 1 diabetes: a systematic review with meta-analysis. *Diabetic medicine*. 2013;30(2):189-98.
6. Ackard DM, Vik N, Neumark-Sztainer D, Schmitz KH, Hannan P, Jacobs Jr DR. Disordered eating and body dissatisfaction in adolescents with type 1 diabetes and a population-based comparison sample: comparative prevalence and clinical implications. *Pediatric diabetes*. 2008;9(4pt1):312-9.
7. Jones JM, Lawson ML, Daneman D, Olmsted MP, Rodin G. Eating disorders in adolescent females with and without type 1 diabetes: cross sectional study. *Bmj*. 2000;320(7249):1563-6.
8. Young-Hyman DL, Davis CL. Disordered eating behavior in individuals with diabetes: importance of context, evaluation, and classification. *Diabetes care*. 2010;33(3):683-9.
9. Colton PA, Olmsted MP, Daneman D, Rydall AC, Rodin GM. Five-year prevalence and persistence of disturbed eating behavior and eating disorders in girls with type 1 diabetes. *Diabetes Care*. 2007;30(11):2861-2.
10. Neumark-Sztainer D, Patterson J, Mellin A, Ackard DM, Utter J, Story M, et al. Weight control practices and disordered eating behaviors among adolescent females and males with type 1 diabetes: associations with sociodemographics, weight concerns, familial factors, and metabolic outcomes. *Diabetes care*. 2002;25(8):1289-96.
11. Borus JS, Laffel L. Adherence challenges in the management of type 1 diabetes in adolescents: prevention and intervention. *Current opinion in pediatrics*. 2010;22(4):405.
12. Bernstein CM, Stockwell MS, Gallagher MP, Rosenthal SL, Soren K. Mental health issues in adolescents and young adults with type 1 diabetes: prevalence and impact on glycemic control. *Clinical Pediatrics*. 2013;52(1):10-5.
13. Stewart SM, Rao U, Emslie GJ, Klein D, White PC. Depressive symptoms predict hospitalization for adolescents with type 1 diabetes mellitus. *Pediatrics*. 2005;115(5):1315-9.
14. Delamater AM, de Wit M, McDarby V, Malik J, Acerini CL. Psychological care of children and adolescents with type 1 diabetes. *Pediatric diabetes*. 2014;15(S20):232-44.
15. Hampson SE, Skinner TC, Hart J, Storey L, Gage H, Foxcroft D, et al. Behavioral interventions for adolescents with type 1 diabetes: how effective are they? *Diabetes Care*. 2000;23(9):1416-22.
16. Hilliard ME, Powell PW, Anderson BJ. Evidence-based behavioral interventions to promote diabetes management in children, adolescents, and families. *American Psychologist*. 2016;71(7):590.

17. Olmsted MP, Daneman D, Rydall AC, Lawson ML, Rodin G. The effects of psychoeducation on disturbed eating attitudes and behavior in young women with type 1 diabetes mellitus. *International Journal of Eating Disorders*. 2002;32(2):230-9.
18. Neff K. Self-compassion: An alternative conceptualization of a healthy attitude toward oneself. *Self and identity*. 2003;2(2):85-101.
19. Marsh IC, Chan SW, MacBeth A. Self-compassion and psychological distress in adolescents—a meta-analysis. *Mindfulness*. 2018;9(4):1011-27.
20. Friis A, Johnson M, Cutfield R, Consedine N. Does kindness matter? Self-compassion buffers the negative impact of diabetes-distress on HbA1c. *Diabetic Medicine*. 2015;32(12):1634-40.
21. Friis AM, Johnson MH, Cutfield RG, Consedine NS. Kindness matters: a randomized controlled trial of a mindful self-compassion intervention improves depression, distress, and HbA1c among patients with diabetes. *Diabetes care*. 2016;39(11):1963-71.
22. Neff KD, Hsieh Y-P, Dejitterat K. Self-compassion, achievement goals, and coping with academic failure. *Self and identity*. 2005;4(3):263-87.
23. Sirois FM, Molnar DS, Hirsch JK. Self-compassion, stress, and coping in the context of chronic illness. *Self and Identity*. 2015;14(3):334-47.
24. Neff KD, Germer CK. A pilot study and randomized controlled trial of the mindful self-compassion program. *Journal of clinical psychology*. 2013;69(1):28-44.
25. Bluth K, Eisenlohr-Moul TA. Response to a mindful self-compassion intervention in teens: A within-person association of mindfulness, self-compassion, and emotional well-being outcomes. *Journal of Adolescence*. 2017;57:108-18.
26. Bluth K, Gaylord SA, Campo RA, Mullarkey MC, Hobbs L. Making friends with yourself: A mixed methods pilot study of a mindful self-compassion program for adolescents. *Mindfulness*. 2016;7(2):479-92.
27. Young-Hyman D, De Groot M, Hill-Briggs F, Gonzalez JS, Hood K, Peyrot M. Psychosocial care for people with diabetes: a position statement of the American Diabetes Association. *Diabetes care*. 2016;39(12):2126-40.
28. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche P, Devereaux P, et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ (Clinical research ed)*. 2010;340:c332.
29. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Annals of internal medicine*. 2013;158(3):200-7.
30. Markowitz JT, Butler DA, Volkening LK, Antisdell JE, Anderson BJ, Laffel LM. Brief screening tool for disordered eating in diabetes: internal consistency and external validity in a contemporary sample of pediatric patients with type 1 diabetes. *Diabetes care*. 2010;33(3):495-500.
31. Cherubini V, Skrami E, Iannilli A, Cesaretti A, Paparusso AM, Alessandrelli MC, et al. Disordered eating behaviors in adolescents with type 1 diabetes: A cross-sectional population-based study in Italy. *International Journal of Eating Disorders*. 2018;51(8):890-8.
32. Storch EA, Ledley DR. Peer victimization and psychosocial adjustment in children: Current knowledge and future directions. *Clinical Pediatrics*. 2005;44(1):29-38.
33. Gilbert P. *Compassion: Conceptualisations, research and use in psychotherapy*: Routledge; 2005.
34. Araia E, Hendrieckx C, Skinner T, Pouwer F, Speight J, King RM. Gender differences in disordered eating behaviors and body dissatisfaction among adolescents with type 1 diabetes: results from diabetes MILES youth—Australia. *International Journal of Eating Disorders*. 2017;50(10):1183-93.

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
35. Wisting L, Frøisland DH, Skrivarhaug T, Dahl-Jørgensen K, Rø Ø. Psychometric properties, norms, and factor structure of the Diabetes Eating Problem Survey–Revised in a large sample of children and adolescents with type 1 diabetes. *Diabetes Care*. 2013;36(8):2198-202.
36. Weinger K, Butler HA, Welch GW, La Greca AM. Measuring diabetes self-care: a psychometric analysis of the Self-Care Inventory-Revised with adults. *Diabetes care*. 2005;28(6):1346-52.
37. Khagram L, Martin CR, Davies MJ, Speight J. Psychometric validation of the Self-Care Inventory-Revised (SCI-R) in UK adults with type 2 diabetes using data from the AT. LANTUS Follow-on study. *Health and quality of life outcomes*. 2013;11(1):24.
38. Vaala SE, Hood KK, Laffel L, Kumah-Crystal YA, Lybarger CK, Mulvaney SA. Use of commonly available technologies for diabetes information and self-management among adolescents with type 1 diabetes and their parents: a web-based survey study. *Interactive journal of medical research*. 2015;4(4):e24.
39. Polonsky WH, Anderson BJ, Lohrer PA, Welch G, Jacobson AM, Aponte JE, et al. Assessment of diabetes-related distress. *Diabetes care*. 1995;18(6):754-60.
40. Schmitt A, Reimer A, Kulzer B, Haak T, Ehrmann D, Hermanns N. How to assess diabetes distress: comparison of the Problem Areas in Diabetes Scale (PAID) and the Diabetes Distress Scale (DDS). *Diabetic Medicine*. 2016;33(6):835-43.
41. Raes F, Pommier E, Neff KD, Van Gucht D. Construction and factorial validation of a short form of the self-compassion scale. *Clinical psychology & psychotherapy*. 2011;18(3):250-5.
42. Neff KD. The development and validation of a scale to measure self-compassion. *Self and identity*. 2003;2(3):223-50.
43. Neff KD, Rude SS, Kirkpatrick KL. An examination of self-compassion in relation to positive psychological functioning and personality traits. *Journal of research in personality*. 2007;41(4):908-16.
44. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. *Journal of health and social behavior*. 1983:385-96.
45. Surwit RS, Van Tilburg MA, Zucker N, McCaskill CC, Parekh P, Feinglos MN, et al. Stress management improves long-term glycemic control in type 2 diabetes. *Diabetes care*. 2002;25(1):30-4.
46. Lee E-H. Review of the psychometric evidence of the perceived stress scale. *Asian nursing research*. 2012;6(4):121-7.
47. Daneman D. Type 1 diabetes. *The Lancet*. 2006;367(9513):847-58.
48. Neff KD, McGehee P. Self-compassion and psychological resilience among adolescents and young adults. *Self and identity*. 2010;9(3):225-40.
49. Serlachius A, Northam E, Frydenberg E, Cameron F. Adapting a generic coping skills programme for adolescents with type 1 diabetes: a qualitative study. *Journal of health psychology*. 2012;17(3):313-23.



Figure 1: Flow of participants through the study






Table 1: Key Exercises and Educational Components of the Brief Self-Compassion

## Intervention for Adolescents

Session one	Session two
Topic: what is self-compassion?	Meditation: Loving kindness meditation
Mindful movement activity: stop and be meditation	Topic: Summary of last week's content
Topic: mindfulness and the wandering mind	Topic: self-esteem vs. self-compassion
Mindful observation activity: here-and-now stone	Discussion: the cost of social comparison
Topic: the adolescent brain	Meditation: Compassionate body scan
Self-compassion exercise: how would I treat a friend?	Group exercise: crossing the line
Self-compassion exercise: comforting gesture	Compassionate letter
Self-compassion exercise: three steps of self-compassion	
Meditation: music meditation	



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Page Number, on which item is reported
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	p.1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	p.2
	2b	All items from the World Health Organization Trial Registration Data Set	na
Protocol version	3	Date and version identifier	p.1
Funding	4	Sources and types of financial, material, and other support	p.17
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	p.1 & 17
	5b	Name and contact information for the trial sponsor	na
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	na
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	na

**Introduction**

1				
2				
3				
4	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	p.4-6
5				
6				
7				
8				
9		6b	Explanation for choice of comparators	p.14
10	Objectives	7	Specific objectives or hypotheses	p.6
11				
12	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	p.7
13				
14				
15				
16				
17				
18				
19	<b>Methods: Participants, interventions, and outcomes</b>			
20				
21	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	p.7
22				
23				
24				
25				
26	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	p.7
27				
28				
29				
30				
31	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	p.8-9
32				
33				
34				
35				
36		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	p.14
37				
38				
39				
40				
41		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	na
42				
43				
44				
45		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	na
46				
47				
48	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	p.10-13
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1				
2				
3				
4	Participant	13	Time schedule of enrolment, interventions (including	
5	timeline		any run-ins and washouts), assessments, and visits for	p.21
6			participants. A schematic diagram is highly	
7			recommended (see Figure)	
8				
9	Sample size	14	Estimated number of participants needed to achieve	
10			study objectives and how it was determined, including	p.7
11			clinical and statistical assumptions supporting any	
12			sample size calculations	
13				
14	Recruitment	15	Strategies for achieving adequate participant	na
15			enrolment to reach target sample size	
16				

### Methods: Assignment of interventions (for controlled trials)

#### Allocation:

19				
20				
21	Sequence	16a	Method of generating the allocation sequence (eg,	
22	generation		computer-generated random numbers), and list of any	
23			factors for stratification. To reduce predictability of a	
24			random sequence, details of any planned restriction	p.10
25			(eg, blocking) should be provided in a separate	
26			document that is unavailable to those who enrol	
27			participants or assign interventions	
28				
29				
30	Allocation	16b	Mechanism of implementing the allocation sequence	
31	concealment		(eg, central telephone; sequentially numbered,	p.10
32	mechanism		opaque, sealed envelopes), describing any steps to	
33			conceal the sequence until interventions are assigned	
34				
35	Implementation	16c	Who will generate the allocation sequence, who will	p.10
36			enrol participants, and who will assign participants to	
37			interventions	
38				
39	Blinding	17a	Who will be blinded after assignment to interventions	
40	(masking)		(eg, trial participants, care providers, outcome	na
41			assessors, data analysts), and how	
42				
43		17b	If blinded, circumstances under which unblinding is	
44			permissible, and procedure for revealing a	na
45			participant's allocated intervention during the trial	
46				
47				

### Methods: Data collection, management, and analysis

48				
49				
50	Data collection	18a	Plans for assessment and collection of outcome,	
51	methods		baseline, and other trial data, including any related	
52			processes to promote data quality (eg, duplicate	
53			measurements, training of assessors) and a description	p.10-13
54			of study instruments (eg, questionnaires, laboratory	
55			tests) along with their reliability and validity, if	
56			known. Reference to where data collection forms can	
57			be found, if not in the protocol	
58				
59				
60				

1				
2				
3				
4		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	na
5				
6				
7				
8				
9	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	na
10				
11				
12				
13				
14				
15				
16	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	p. 13
17				
18				
19				
20				
21				
22		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	p.13
23				
24				
25		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	p.13
26				
27				
28				
29				
30	<b>Methods: Monitoring</b>			
31				
32	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	na
33				
34				
35				
36				
37				
38				
39				
40				
41		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	na
42				
43				
44				
45				
46	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	p. 14
47				
48				
49				
50				
51	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	na
52				
53				
54				
55				

### Ethics and dissemination

1				
2				
3				
4	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	p.14
5				
6				
7				
8	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	p.7
9				
10				
11				
12				
13				
14	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	p.10
15				
16				
17				
18		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	na
19				
20				
21				
22	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	na
23				
24				
25				
26				
27				
28	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	p.16
29				
30				
31	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	na
32				
33				
34				
35	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	p.14
36				
37				
38				
39				
40	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	p.14
41				
42				
43				
44				
45				
46				
47		31b	Authorship eligibility guidelines and any intended use of professional writers	p.17
48				
49				
50		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	na
51				
52				
53				
54	<b>Appendices</b>			
55				
56	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	na
57				
58				
59				
60				

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Biological specimens

33 Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable

na

For peer review only

# BMJ Open

## Protocol for a feasibility study: A brief self-compassion intervention for adolescents with type 1 diabetes and disordered eating

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034452.R1
Article Type:	Protocol
Date Submitted by the Author:	19-Dec-2019
Complete List of Authors:	Boggiss, Anna; The University of Auckland Faculty of Medical and Health Sciences, Psychological Medicine Consedine, Nathan; The University of Auckland Faculty of Medical and Health Sciences, Psychological Medicine Jefferies, Craig; Starship Children's Health, Auckland City Hospital Bluth, Karen; University of North Carolina at Chapel Hill, Psychiatry Hofman, Paul; The University of Auckland Liggins Institute Serlachius, Anna; The University of Auckland Faculty of Medical and Health Sciences, Psychological Medicine
<b>Primary Subject Heading</b>:	Mental health
Secondary Subject Heading:	Diabetes and endocrinology
Keywords:	self-compassion, adolescence, disordered eating, type 1 diabetes, psychosocial interventions, clinically usable interventions

SCHOLARONE™  
Manuscripts





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Protocol for a feasibility study: A brief self-compassion intervention for adolescents**  
4  
5 **with type 1 diabetes and disordered eating**  
6  
7  
8  
9

10 Anna L. Boggiss, PGDip<sup>1</sup>, Nathan S. Consedine, PhD<sup>1</sup>, Craig Jefferies, MD<sup>2</sup>, Karen Bluth,  
11 PhD<sup>3</sup>, Paul L. Hofman, MD<sup>4</sup>, and Anna S. Serlachius, PhD<sup>1</sup>  
12  
13

14 <sup>1</sup>Department of Psychological Medicine, Faculty of Medical and Health Sciences, University  
15 of Auckland, Auckland, New Zealand  
16  
17

18 <sup>2</sup>Starship Children's Health, Auckland City Hospital, Auckland, New Zealand  
19  
20

21 <sup>3</sup>Department of Psychiatry, University of North Carolina, Chapel Hill, United States of  
22 America  
23  
24

25 <sup>4</sup>Liggins Institute, University of Auckland, Auckland, New Zealand  
26  
27

28 Corresponding author: Anna Boggiss, Department of Psychological Medicine, University of  
29 Auckland, Auckland, New Zealand. Email: abog579@aucklanduni.ac.nz. Phone number +64  
30 9 923 3073.  
31  
32  
33  
34  
35  
36

37 *Keywords: self-compassion, adolescence, disordered eating, type 1 diabetes,*  
38 *psychosocial interventions, clinically usable interventions*  
39  
40

41  
42 Tables/Figures: 1 table and 1 figure (attached in a separate file)  
43  
44

45 Word count: 3,656  
46

47 Dates of the study: recruitment started 24<sup>th</sup> May 2019, recruitment estimated to be complete  
48 by early November 2019, data collection estimated to be complete by late January 2020  
49  
50

51 Issue date: 20 Sep 2019  
52

53 Protocol amendment number: 02  
54

55 Authors: AB, NS, PH, KB, AS  
56  
57  
58  
59  
60

## Abstract

**Introduction:** Adolescents with type 1 diabetes are at a higher risk of developing psychiatric disorders, particularly eating disorders, compared to their healthy peers. In turn, this increases the risk for sub-optimal glycaemic control and life-threatening diabetes-related complications. Despite these increased risks, standard diabetes care does not routinely provide psychological support to help prevent or reduce mental health risks. There is an urgent need to develop ‘clinically usable’ psychosocial interventions, that are acceptable to patients and can be realistically integrated into clinical care. This study aims to examine the feasibility and acceptability of a brief self-compassion intervention for adolescents with type 1 diabetes and disordered eating behaviour.

**Methods and analysis:** This feasibility study will examine the effectiveness of a brief self-compassion intervention, compared to a waitlist control group. Participants aged 12-16 years will be recruited from three diabetes outpatient clinics in Auckland, New Zealand. The brief self-compassion intervention is adapted from the standardised ‘Making Friends with Yourself’ (MFY) intervention and will be delivered in a group format over two sessions. As well as examining feasibility and acceptability through the flow of participants through the study and qualitative questions, we will assess changes to disordered eating behaviour (primary outcome), self-care behaviours, diabetes-related distress, self-compassion, stress and glycaemic control (secondary outcomes). Such data will be used to calculate the required sample size for a fully powered RCT.

**Ethics and dissemination:** The current trial has received ethics approval from the Health and Disability Ethics Committee (HDEC; research project number A+8467). Study results will be disseminated through peer-reviewed journals and conferences.

**Trial registration number:** ANZCTR (12619000541101).

**Strengths and Limitations:**

- The study will be the first to examine self-compassion as a potential therapeutic approach to the widespread problem of disordered eating behaviour in adolescents with type 1 diabetes.
- Qualitative data, changes to self-reported psychological health, and HbA1C will be used to examine the program's feasibility, acceptability and to estimate the magnitude of any effect of self-compassion on disordered eating behaviour.
- The study is limited by the lack of blinding by the first author.
- The study is a feasibility trial and therefore will not be able to determine the efficacy of the brief self-compassion program.
- Overall, the study will contribute to the future research agenda of developing a 'clinically usable' self-compassion intervention for adolescents with type 1 diabetes.

## Introduction

This protocol paper describes a feasibility study designed to evaluate the feasibility, acceptability, and estimate of the effect of a brief self-compassion intervention for adolescents with type 1 diabetes (T1D) and disordered eating behaviours. Adolescents with T1D face the dual challenge of learning how to manage their chronic condition while concurrently dealing with what can be normatively difficult developmental changes. Maintaining optimal self-management of T1D requires adherence to a complicated routine of daily self-administration of insulin and monitoring diet, energy expenditure and blood glucose levels (1). Adolescents must learn how to make these complex routines flexible enough to implement into their daily life including school, hobbies and other activities (2). Unsurprisingly, diabetes self-management tends to deteriorate during adolescence, with adolescents showing sub-optimal glycaemic control and higher rates of complications compared to adults or younger children (3).

Adolescents with T1D also show much greater rates of psychological disorders, especially eating disorders, than their healthy peers (4, 5). In a recent national Australian study of adolescents with T1D, 50% of female and 18% of male adolescents scored over the cut-off for disordered eating behaviour (6). Eating disorders have also been shown to be twice as common in adolescent females with T1D compared to their healthy peers (7) and rates of disordered eating in adolescents with T1D are rising (8, 9). Given that behaviours such as insulin omission and purging are associated with increases in diabetes-related complications (6, 10), this is concerning. Poor psychological health, including disordered eating, has the potential to make daily self-management decisions even more challenging and has known associations with lower rates of glucose testing and insulin adherence (11), poorer glycaemic control (12) and more frequent hospitalisations and complications (13). Therefore,

1  
2  
3 prioritising psychological health and wellbeing is an essential component of successful  
4  
5 diabetes care and may be even more relevant during adolescence.  
6

7  
8 Despite the high prevalence of mental health disorders among adolescents with T1D,  
9  
10 treatment options are limited. Current interventions to target psychological issues include  
11  
12 psychopharmacology (such as antidepressants) and psychosocial interventions. Research has  
13  
14 shown that individual and group-based interventions focused on improving family  
15  
16 relationships, stress management, and coping skills can improve adherence, glycaemic  
17  
18 control and quality of life (14). However, such interventions are rarely incorporated into  
19  
20 standard diabetes care due to funding constraints and a lack of therapist availability (15, 16),  
21  
22 as well as the logistical issues associated with family therapies. Furthermore, only one study  
23  
24 has examined the use of an intervention specifically targeting disordered eating behaviour in  
25  
26 adolescents with T1D (17). There is thus a strong need to develop interventions to treat  
27  
28 psychological distress, especially disordered eating behaviour, that are acceptable to  
29  
30 adolescents with T1D and can be realistically incorporated into routine clinical care.  
31  
32  
33

34  
35 Self-compassion is an emerging approach which may offer an effective method to  
36  
37 improve psychological health and self-management among adolescents with T1D. Self-  
38  
39 compassion appears highly relevant to the self-criticisms that commonly arise following  
40  
41 difficulty adhering to complex self-management regimens. At its core, self-compassion is  
42  
43 characterised by: (1) being aware of one's moment to moment experiences with a sense of  
44  
45 emotional balance and non-judgement (mindfulness), (2) acknowledging that suffering and  
46  
47 imperfection are part of being human (common humanity), and (3) taking an active role in  
48  
49 being caring and understanding toward oneself (self-kindness) (18). Lower self-compassion  
50  
51 has been closely linked to greater depression and anxiety (19), including in adults with  
52  
53 diabetes (20, 21), while higher self-compassion is associated with less rumination, self-  
54  
55 criticism, perfectionism, and fear of failure (18, 22). Self-compassion has demonstrated  
56  
57  
58  
59  
60

1  
2  
3 benefits for those with chronic illnesses (including inflammatory bowel disease and arthritis),  
4 such as improved self-management and coping (23). Most recently, a standardised 8-week  
5 self-compassion programme for adolescents, ‘Making Friends with Yourself’ (MFY),  
6 adapted from the Mindful Self-Compassion (MSC) Program for adults (24), showed  
7 significant improvements in self-compassion, life satisfaction and depression, compared to a  
8 waitlist control group, in healthy adolescents (23). Mindfulness, social connectedness,  
9 anxiety, stress, resilience, curiosity and gratitude have also been shown to increase  
10 throughout the MFY programme (25, 26).  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

21 To date, MFY has not been trialled in adolescents with diabetes or any other chronic  
22 illness. However, a recent RCT compared the 8-week MSC Programme for adults with  
23 diabetes to a waitlist control group (21). Researchers found increased self-compassion was  
24 associated with reductions in diabetes-related distress, depression, and improvements in  
25 glycaemic control, both at post-intervention and at the 3-month follow-up compared to the  
26 waitlist control group.  
27  
28  
29  
30  
31  
32  
33  
34

35 Considering the vital role psychological health plays in diabetes-related outcomes  
36 (27) and the conceptual fit between the purpose of self-compassion training and the issues  
37 confronting adolescents with T1D, we developed a brief (2-session) self-compassion  
38 intervention targeted to adolescents with T1D and disordered eating behaviour. The current  
39 study will examine the programme’s feasibility and acceptability for adolescents with T1D  
40 and provide estimates of change in psychological and physical health outcomes. It is  
41 hypothesised that the brief self-compassion intervention will improve disordered eating  
42 behaviours, self-care behaviours, diabetes-related distress, self-compassion, stress and  
43 glycaemic control, compared to the waitlist control group at post-intervention.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

## 55 **Methods and analysis**

### 56 **Design overview**

1  
2  
3 The study is a feasibility study of a brief self-compassion intervention (treatment  
4 group), compared to a waitlist control group, in 28 adolescents with T1D. The study will be  
5 conducted in accordance to the CONSORT guidelines (28) and has been prospectively  
6 registered in the Australian New Zealand Clinical Trials Registry (ANZCTR  
7 12619000541101). The SPIRIT recommendations were adhered to in reporting the protocol  
8 (29).  
9

### 16 **Participants**

17  
18  
19 Participants in the study are adolescents with T1D who are currently being recruited  
20 from three paediatric and adolescent diabetes clinics in Auckland, New Zealand. Adolescents  
21 are eligible for inclusion in the study if they meet the following criteria: (1) are aged 12 to 16  
22 years, (2) diagnosed with T1D more than 6 months ago at time of recruitment and (3)  
23 demonstrate moderate to high instances of disordered eating behaviour on the Diabetes  
24 Eating Problem Survey Revised (DEPS-R) (30) screening tool. A moderate to high  
25 disordered eating behaviour cut-off score was chosen to allow more room to detect changes  
26 and to offer the interventions to those at the highest risk. Exclusion criteria includes: (1) non-  
27 English speaking adolescents, (2) adolescents with developmental disorders (e.g. Autism  
28 Spectrum Disorder), (3) adolescents diagnosed with a serious mental disorder requiring  
29 ongoing treatment (e.g., psychosis), (4) children with untreated hypothyroidism, and (5)  
30 children recently (in previous 48 hours) diagnosed with DKA or severe hypoglycaemia. See  
31 Figure 1 for an overview of the proposed flow of participants through the study.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

### 49 **Sample size calculation**

50  
51 Based on other studies suggesting the prevalence of disordered eating of 27% for boys  
52 and 42% for girls in T1D (31), we estimated that we would need to screen approximately 50  
53 adolescents to enroll at least 20 adolescents (who score over the cut-off on the DEPS-R). We  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 will use the observed changes in psychological outcomes (e.g., DEPS-R) and physical health  
4  
5 outcomes to calculate the required sample size for a subsequent fully powered RCT.  
6  
7

### 8 **Intervention development**

9  
10 The brief self-compassion intervention was adapted from the 8-week MFY  
11 programme (25), in consultation with Karen Bluth and five other trained MFY and MSC  
12 teachers. Components from the MFY programme were chosen for the brief adaption because  
13 they are: (1) foundational exercises covering the basics of mindfulness and self-compassion  
14 and (2) address body image concerns and feelings of isolation, which have been highlighted  
15 in the literature to be relevant to adolescents with T1D (32). These components included  
16 group exercises and discussions, topics, art activities, meditations and individual reflection  
17 exercises (see Table 1).  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

### 28 **Brief self-compassion intervention**

29  
30 The brief self-compassion intervention will involve two 2-hour sessions conducted at  
31 the University of Auckland. The intervention sessions will be facilitated by the first author  
32 (A.B), a trained MFY teacher.  
33  
34  
35  
36

37 As summarised in Table 1, Session 1 will focus on giving participants an  
38 understanding of mindfulness through several tangible activities including a mindful  
39 movement activity, group discussions and a mindful activity using a stone or shell.  
40 Psychoeducation around adolescent brain development and emotion regulation systems (33)  
41 will be taught to help to establish the reasons why mindfulness and self-compassion can help  
42 with managing stress, especially in adolescence. Regarding self-compassion, the 'How  
43 Would I Treat a Friend' exercise offers an interactive method of explaining self-compassion  
44 before practicing the self-compassion coping skills of 'Comforting Gesture' (i.e. 'Soothing  
45 Touch') and the 'Three Steps of Self-Compassion' (i.e. 'A Moment for Me').  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1: Key Exercises and Educational Components of the Brief Self-Compassion Intervention for Adolescents

Session one	Session two
Topic: what is self-compassion?	Meditation: Loving kindness meditation
Mindful movement activity: stop and be meditation	Topic: Summary of last week's content
Topic: mindfulness and the wandering mind	Topic: self-esteem vs. self-compassion
Mindful observation activity: here-and-now stone	Discussion: the cost of social comparison
Topic: the adolescent brain	Meditation: Compassionate body scan
Self-compassion exercise: how would I treat a friend?	Group exercise: crossing the line
Self-compassion exercise: comforting gesture	Compassionate letter
Self-compassion exercise: three steps of self-compassion	
Meditation: music meditation	

The 'How Would I Treat a Friend' exercise shows adolescents that they often treat themselves much more harshly than they treat their friends through exploring their reactions to how they would treat themselves versus their friends in difficult situations, such as receiving a bad mark on an important test. Finding a 'Comforting Gesture' (such as holding your hands over your heart or stomach), involves practicing applying self-compassion to soothe and regulate emotions during stressful situations in one's life. The 'Three Steps of Self-Compassion' involves applying the three elements of self-compassion (mindfulness, common humanity and self-kindness) to cope with difficult emotions.

Session 2 is focused on developing coping skills to deal with body image concerns and feelings of isolation. Opening with a loving-kindness meditation will provide a reminder

1  
2  
3 of the concept of self-compassion and the 'Comforting Gesture' tool from Session 1 before  
4  
5 summarising the content taught in the last session. Self-esteem versus self-compassion and  
6  
7 the cost of social comparison is then discussed to help teens understand how comparing  
8  
9 themselves to others can create suffering and to allow them to practice using the coping skills  
10  
11 taught in Session 1 when they experience feelings of inadequacy. The 'Crossing the Line'  
12  
13 group activity then emphasises the common humanity element of self-compassion by asking  
14  
15 adolescents to cross a line of string if they have experienced certain feelings or situations,  
16  
17 such as feelings of isolation, been bullied or having compared themselves to their friends or  
18  
19 an image in the media. Adolescents will then practice a compassionate body scan meditation  
20  
21 and writing themselves a compassionate letter as further skills to use surrounding body image  
22  
23 concerns.  
24  
25  
26  
27

28 Handbooks will be given to participants to review topics and outline the coping skills  
29  
30 taught in the sessions, with examples of situations where it may be helpful to use them.  
31  
32 Recordings of the meditations used in the sessions will also be emailed to the participant's  
33  
34 parent/ caregiver and the participant.  
35  
36

### 37 **Study procedure**

38  
39 The study started recruitment on the 24<sup>th</sup> of May 2019 and is estimated to finish in  
40  
41 late October 2019. Figure 1 depicts the flow of participants through the trial. Eligible families  
42  
43 will be invited by diabetes nurse educators at their Paediatric Diabetes Service clinic  
44  
45 appointments to participate in a study investigating body image concerns in adolescents with  
46  
47 T1D. Interested participants will be referred to the first author (A.B), who will verbally  
48  
49 explain the study to interested families. Once consent/ assent is given, the adolescents will  
50  
51 complete the DEPS-R screening tool. Participants who score over the cut-off score for  
52  
53 moderate disordered eating behaviour, will then be randomised to either the treatment group  
54  
55 or a waitlist control group (who will receive the intervention after the treatment group has  
56  
57  
58  
59  
60

1  
2  
3 completed post-intervention measures) on a 1:1 basis. Randomisation will occur via sealed  
4 envelopes labelled with sequential study numbers, prepared by a biostatistician independent  
5 of the study. As the first author (A.B) is responsible for both recruitment and teaching the  
6 program, blinding is unable to occur.  
7  
8  
9  
10

11  
12 After randomisation, participants will also complete standardised questionnaires  
13 measuring self-care behaviours, diabetes-related distress, self-compassion and stress in clinic  
14 or online. After completing the intervention, participants will be given the same  
15 questionnaires as well as open-ended questions to assess the acceptability and feasibility of  
16 the programme. Participants in the waitlist control will then start the intervention.  
17  
18  
19  
20  
21  
22

### 23 **Outcome measures**

24  
25 The primary goal of this feasibility study is to determine the feasibility and  
26 acceptability of the brief self-compassion intervention in the service of designing a larger,  
27 multi-centred, powered study. This will be assessed by evaluating whether adolescents with  
28 T1D are willing to participate in the intervention (i.e. recruitment and uptake), reasons for not  
29 wanting to participate, the acceptability of the delivered intervention (assessed via qualitative  
30 questions), study attrition rate and the suitability of the outcome measures. Qualitative data,  
31 through questionnaires at post-intervention, will also be used to refine the intervention  
32 content and comment on strengths and weaknesses of the program.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 In addition, the following psychological and physical health outcomes will be  
45 assessed to give preliminary estimates of effect sizes to estimate the sample size needed for a  
46 fully-powered RCT:  
47  
48  
49

- 50  
51 1. Disordered eating behaviour as measured by the Diabetes Eating Problem Survey  
52 Revised (DEPS-R) (30). The DEPS-R is a 16-item diabetes-specific self-report  
53 measure of disordered eating. Participants are asked how true each item is for  
54 them (e.g., 'I feel fat when I take all of my insulin') on a 6-point Likert scale  
55  
56  
57  
58  
59  
60

(0=never to 6=always), with items summed to produce a total score. The scale has demonstrated good reliability ( $\alpha=0.86-0.91$ ) and validity in adolescents with diabetes samples (30, 34, 35). For the current study, the moderate disordered eating cut-off ( $\geq 10$ ) for inclusion in the study will be used. DEPS-R results for all adolescents screened for eligibility will be reported to give an indication of prevalence of moderate disordered eating behaviour in the Pediatric Diabetes clinics.

2. Self-care behaviours as measured by the Self Care Inventory-Revised Version (SCI-R) (36). The SCI-R is a 15-item questionnaire which assesses how often diabetes self-care behaviours have been adhered to over the past one to two months on a 5-point Likert scale (1=never to 5=always). The self-care behaviours assessed include the main components of the type 1 diabetes self-management routine such as monitoring and recording glucose levels, administering and adjusting insulin and regulating meals and exercise. Items will be averaged and converted to a 0-100-point scale to produce a total score, with higher values representing better self-care. The scale has shown good reliability ( $\alpha=0.77-0.78$ ) and validity (37, 38).
3. Diabetes-related distress as measured by Problem Areas in Diabetes Survey (PAID) (39). The 20-item questionnaire lists common negative emotions related to living with diabetes such as, 'feeling alone with diabetes', and 'worrying about the future and the possibility of serious complications'. The 20-items are measured on a 6-point Likert scale (1=not a problem to 6=a serious problem), with items averaged to produce a total score. The scale demonstrates good reliability ( $\alpha=0.93$ ) and validity (40).

- 1  
2  
3 4. Self-compassion as measured by the Self-Compassion Scale, short form (SCS-SF)  
4  
5 (41). The 12 items are measured on a 5-point Likert scale (1=almost never to  
6  
7 5=almost always), with items averaged to create a total score. Example items  
8  
9 include: ‘when I fail at something important to me I become consumed by feelings  
10  
11 of inadequacy’ and ‘when I’m feeling down I tend to obsess and fixate on  
12  
13 everything that’s wrong’. Reliability for this scale is good with a Cronbach alpha  
14  
15 of  $\alpha = 0.77-.79$  (25, 26) in adolescent samples. Strong predictive, convergent and  
16  
17 discriminant validity has also been demonstrated (42, 43).  
18  
19
- 20  
21 5. Stress as measured by the Perceived Stress Scale (PSS) (44). The questionnaire  
22  
23 assesses feelings of stress, hassles and coping during the past month. For example,  
24  
25 ‘in the last month, how often have you felt that you were unable to control the  
26  
27 important things in your life?’. The 14-items are measured on a 5-point Likert  
28  
29 scale (0=never to 4=very often), with the score of each item combined to produce  
30  
31 a total score. The scale has been shown to associate with glycaemic control (45)  
32  
33 and demonstrates good reliability ( $\alpha=0.75-.88$ ) and validity (46).  
34  
35
- 36  
37 6. Glycaemic control as measured by Glycosylated haemoglobin (HbA<sub>1C</sub>). HbA<sub>1C</sub> is  
38  
39 a blood test collected during routine outpatient appointments (which occur every  
40  
41 3-4 months), which is a reliable measure of blood glucose control over a period of  
42  
43 3-4 months. HbA<sub>1C</sub> is measured in millimoles per mol (mmol/mol), with lower  
44  
45 values indicating better glycaemic control (47). HbA<sub>1C</sub> ranges from 31 to 108  
46  
47 mmol/mol, with the ideal target for all child and adolescent age groups being  
48  
49 below 58 mmol/mol (1). HbA<sub>1C</sub> levels will be accessed from clinical records at  
50  
51 baseline and post-intervention (window of 12-16 weeks after baseline).  
52  
53  
54  
55  
56

## 57 **Data analysis plan**

58  
59  
60

1  
2  
3 Descriptive statistics will be reported for proportion of adolescents who were  
4  
5 screened and who scored over the cut-off for the DEPS-R, rates of disordered eating across  
6  
7 all adolescents screened, number of adolescents who attended the sessions, and number of  
8  
9 adolescents who dropped out of the study. Data will be tested for violations of statistical  
10  
11 assumptions. If parametric assumptions are not met, the Mann-Whitney test will compare the  
12  
13 two groups at time 2 and Wilcoxon signed-ranks test will analyse possible within-group  
14  
15 improvements. Means, standard deviations and 95% confidence intervals will be reported  
16  
17 with the analyses. Pearson's correlations will be used to explore the relationships between the  
18  
19 different outcome measures, demographic characteristics, disease characteristics, and current  
20  
21 insulin regimen. An independent samples t-test will be conducted at post-intervention (see  
22  
23 time 2, Figure 1) and will be our main analysis to test our hypothesis for differences between  
24  
25 the intervention group and waitlist control group in disordered eating behaviour, diabetes-  
26  
27 related distress, stress, self-care behaviours and self-compassion. An independent samples t-  
28  
29 test will also be conducted at the 12-week follow-up to assess any possible differences  
30  
31 between groups for glycaemic control. In addition, to increase sample size and statistical  
32  
33 power, an exploratory analysis will combine post-intervention data from participants in the  
34  
35 treatment group (at time 2) and participants in the waitlist control group (at time 3) to  
36  
37 examine within and between group changes from baseline, using paired samples t-tests. An  
38  
39 intention to treat analysis is planned.

40  
41  
42 These effect size estimates will also allow us to estimate the required sample size for  
43  
44 a future RCT. Mean differences, standard deviations and sample size will be used to  
45  
46 calculate an estimated Cohen's d for the effect of the intervention on disordered eating  
47  
48 behaviour, which we will then use to calculate our required sample size.

## 49 50 51 **Patient and Public Involvement**

52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Patients, carers and members of the public were not involved in the study design  
4  
5 phases of the current study. However, during the recruitment process patients who choose not  
6  
7 to participate will be asked to assess whether the time commitment or required travel was a  
8  
9 reason for not choosing to participate, when possible. In addition, patients who participate in  
10  
11 the sessions will also provide qualitative feedback on the burden of participating, the  
12  
13 recruitment process and the format and content of the sessions to inform the future RCT.  
14  
15 Regarding dissemination of results, during recruitment we ask patients whether they consent  
16  
17 to the findings being disseminated via peer reviewed journal articles and conferences. We  
18  
19 also ask whether they would like to be informed of the results at the end of the study and how  
20  
21 (e.g. email/post). Patients who agree to being informed of the study results are sent a letter  
22  
23 with the key findings and any publications arising from the study. In some cases, patients  
24  
25 may also be invited to a departmental presentation of the study findings.  
26  
27  
28  
29

### 30 **Ethics and dissemination**

31  
32 The study was approved by the Health and Disability Ethics Committee (HDEC;  
33  
34 research project number A+8467). Due to screening for and only including adolescents with  
35  
36 disordered eating behaviour, it was recommended to include a waitlist control group (rather  
37  
38 than a standard care control group) in order to offer all eligible participants the intervention.  
39  
40 Participants who report significant psychological concerns, such as self-harm, or issues  
41  
42 relating to their diabetes that fall outside of the scope of the intervention, such as complex  
43  
44 self-management concerns, will be referred to the diabetes team psychologist. The paediatric  
45  
46 and adolescent diabetes team (including endocrinologists, diabetes nurse educators, dieticians  
47  
48 and a psychologist) will provide study support throughout the trial, including monitoring any  
49  
50 adverse events. Study results will be disseminated through peer-reviewed journals, a doctoral  
51  
52 thesis, and conference presentations.  
53  
54  
55  
56  
57

### 58 **Discussion**



1  
2  
3 To our knowledge, the current study will be the first to assess the acceptability of self-  
4 compassion intervention for adolescents with T1D and examine the feasibility of a brief  
5  
6 adaption of the MFY programme. The intervention addresses the rising concern of disordered  
7  
8 eating in adolescents with T1D (8, 9), building on the sparse literature in this area (17). The  
9  
10 intervention will aim to teach adolescents evidence-based mindfulness and self-compassion  
11  
12 skills to help them cope with stress, difficult emotions, self-management obstacles, and body  
13  
14 image concerns and to determine whether self-compassion is a feasible and acceptable  
15  
16 approach. As the prevalence and impact of these psychological concerns in adolescents with  
17  
18 T1D is a current obstacle in diabetes care, the study will help determine whether self-  
19  
20 compassion is a feasible and acceptable approach.  
21  
22  
23  
24  
25

26 The novelty of testing self-compassion for adolescents with T1D and the brief format  
27  
28 of the intervention are key strengths of this study. Firstly, although self-compassion has  
29  
30 previously demonstrated efficacy in adults with diabetes (21) we believe it may be even more  
31  
32 beneficial for adolescents with T1D. Adolescence is a period of vulnerability with an  
33  
34 increased risk for self-criticism, poor self-esteem, and body image concerns (48). In  
35  
36 adolescents with T1D these concerns are exacerbated by difficult self-management routines  
37  
38 and parental conflict surrounding their diabetes-care (49), as well as increased risk of  
39  
40 psychological distress and feelings of isolation (32). Self-compassion may encourage  
41  
42 adolescents to be more accepting and kind to themselves when facing these issues, without  
43  
44 engaging in problematic or counterproductive self-criticism. The common humanity aspect of  
45  
46 self-compassion is likely to help validate feelings that emerge from any struggles they are  
47  
48 experiencing, such as feelings of isolation, feeling less than, stress and sadness, as normal and  
49  
50 common to all teens.  
51  
52  
53  
54

55 An adapted version of the 'Making Friends with Yourself' programme to a brief (2-  
56  
57 session format) was chosen to address the lack of 'clinically usable' interventions in diabetes  
58  
59  
60

1  
2  
3 care. Although it is widely acknowledged that psychological care is a key component of  
4  
5 improving health outcomes in diabetes (16, 27), the integration of psychosocial care into  
6  
7 routine diabetes care remains lacking. Despite the growing literature demonstrating the  
8  
9 efficacy of psychosocial interventions for improving psychological outcomes in T1D,  
10  
11 interventions are rarely designed with the intention of being ‘clinically usable’ and in a  
12  
13 format that could potentially be adopted into standard care.  
14  
15

16  
17 Altogether, our aim is to examine the feasibility and acceptability of a brief self-  
18  
19 compassion intervention, as well as provide effect size estimates. If the brief self-compassion  
20  
21 intervention is found to be feasible and acceptable to adolescents, future plans include  
22  
23 conducting a fully powered RCT to examine the long-term efficacy of the intervention, with  
24  
25 the intention of developing a clinically usable psychosocial intervention for youth with both  
26  
27 T1D and disordered eating behaviours.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Authors contributions:** A.B, P.H and A.S came up with the conception and design of the  
4 study. A.B will be recruiting participants and conducting the program sessions. P.H and C.J  
5 will provide guidance and assistance with recruitment. K.B provided training and  
6 consultation during the program development phase and will provide A.B with supervision  
7 throughout the sessions. A.B. and A.S. wrote the manuscript. N.C., P.H, C.J and K.B  
8 reviewed and edited the manuscript.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

19 **Funding statement:** This research received no specific grant from any funding agency in the  
20 public, commercial or not-for-profit sectors.  
21  
22  
23  
24  
25

26 **Competing interests statement:** The authors declare that they have no conflicts of interest.  
27  
28  
29

30 **Figure 1 Legend:** CONSORT flow diagram showing the proposed flow of participants  
31 (n=28) through each stage of the feasibility trial (enrolment, disordered eating screening,  
32 baseline assessment, randomisation to either intervention group or waitlist control, time 2  
33 assessment, time 3 assessment and collection of HbA1c).  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


## References

1. Association AD. Standards of medical care in diabetes—2017 abridged for primary care providers. *Clinical diabetes: a publication of the American Diabetes Association*. 2017;35(1):5.
2. Chiang JL, Kirkman MS, Laffel LM, Peters AL. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. *Diabetes care*. 2014;37(7):2034-54.
3. Moore SM, Hackworth NJ, Hamilton VE, Northam EP, Cameron FJ. Adolescents with type 1 diabetes: parental perceptions of child health and family functioning and their relationship to adolescent metabolic control. *Health and quality of life outcomes*. 2013;11(1):50.
4. Reynolds KA, Helgeson VS. Children with diabetes compared to peers: depressed? Distressed? A meta-analytic review. *Annals of Behavioral Medicine*. 2011;42(1):29-41.
5. Young V, Eiser C, Johnson B, Brierley S, Epton T, Elliott J, et al. Eating problems in adolescents with Type 1 diabetes: a systematic review with meta-analysis. *Diabetic medicine*. 2013;30(2):189-98.
6. Ackard DM, Vik N, Neumark-Sztainer D, Schmitz KH, Hannan P, Jacobs Jr DR. Disordered eating and body dissatisfaction in adolescents with type 1 diabetes and a population-based comparison sample: comparative prevalence and clinical implications. *Pediatric diabetes*. 2008;9(4pt1):312-9.
7. Jones JM, Lawson ML, Daneman D, Olmsted MP, Rodin G. Eating disorders in adolescent females with and without type 1 diabetes: cross sectional study. *Bmj*. 2000;320(7249):1563-6.
8. Young-Hyman DL, Davis CL. Disordered eating behavior in individuals with diabetes: importance of context, evaluation, and classification. *Diabetes care*. 2010;33(3):683-9.
9. Colton PA, Olmsted MP, Daneman D, Rydall AC, Rodin GM. Five-year prevalence and persistence of disturbed eating behavior and eating disorders in girls with type 1 diabetes. *Diabetes Care*. 2007;30(11):2861-2.
10. Neumark-Sztainer D, Patterson J, Mellin A, Ackard DM, Utter J, Story M, et al. Weight control practices and disordered eating behaviors among adolescent females and males with type 1 diabetes: associations with sociodemographics, weight concerns, familial factors, and metabolic outcomes. *Diabetes care*. 2002;25(8):1289-96.
11. Borus JS, Laffel L. Adherence challenges in the management of type 1 diabetes in adolescents: prevention and intervention. *Current opinion in pediatrics*. 2010;22(4):405.
12. Bernstein CM, Stockwell MS, Gallagher MP, Rosenthal SL, Soren K. Mental health issues in adolescents and young adults with type 1 diabetes: prevalence and impact on glycemic control. *Clinical Pediatrics*. 2013;52(1):10-5.
13. Stewart SM, Rao U, Emslie GJ, Klein D, White PC. Depressive symptoms predict hospitalization for adolescents with type 1 diabetes mellitus. *Pediatrics*. 2005;115(5):1315-9.
14. Delamater AM, de Wit M, McDarby V, Malik J, Acerini CL. Psychological care of children and adolescents with type 1 diabetes. *Pediatric diabetes*. 2014;15(S20):232-44.
15. Hampson SE, Skinner TC, Hart J, Storey L, Gage H, Foxcroft D, et al. Behavioral interventions for adolescents with type 1 diabetes: how effective are they? *Diabetes Care*. 2000;23(9):1416-22.
16. Hilliard ME, Powell PW, Anderson BJ. Evidence-based behavioral interventions to promote diabetes management in children, adolescents, and families. *American Psychologist*. 2016;71(7):590.

17. Olmsted MP, Daneman D, Rydall AC, Lawson ML, Rodin G. The effects of psychoeducation on disturbed eating attitudes and behavior in young women with type 1 diabetes mellitus. *International Journal of Eating Disorders*. 2002;32(2):230-9.
18. Neff K. Self-compassion: An alternative conceptualization of a healthy attitude toward oneself. *Self and identity*. 2003;2(2):85-101.
19. Marsh IC, Chan SW, MacBeth A. Self-compassion and psychological distress in adolescents—a meta-analysis. *Mindfulness*. 2018;9(4):1011-27.
20. Friis A, Johnson M, Cutfield R, Consedine N. Does kindness matter? Self-compassion buffers the negative impact of diabetes-distress on HbA1c. *Diabetic Medicine*. 2015;32(12):1634-40.
21. Friis AM, Johnson MH, Cutfield RG, Consedine NS. Kindness matters: a randomized controlled trial of a mindful self-compassion intervention improves depression, distress, and HbA1c among patients with diabetes. *Diabetes care*. 2016;39(11):1963-71.
22. Neff KD, Hsieh Y-P, Dejitterat K. Self-compassion, achievement goals, and coping with academic failure. *Self and identity*. 2005;4(3):263-87.
23. Sirois FM, Molnar DS, Hirsch JK. Self-compassion, stress, and coping in the context of chronic illness. *Self and Identity*. 2015;14(3):334-47.
24. Neff KD, Germer CK. A pilot study and randomized controlled trial of the mindful self-compassion program. *Journal of clinical psychology*. 2013;69(1):28-44.
25. Bluth K, Eisenlohr-Moul TA. Response to a mindful self-compassion intervention in teens: A within-person association of mindfulness, self-compassion, and emotional well-being outcomes. *Journal of Adolescence*. 2017;57:108-18.
26. Bluth K, Gaylord SA, Campo RA, Mullarkey MC, Hobbs L. Making friends with yourself: A mixed methods pilot study of a mindful self-compassion program for adolescents. *Mindfulness*. 2016;7(2):479-92.
27. Young-Hyman D, De Groot M, Hill-Briggs F, Gonzalez JS, Hood K, Peyrot M. Psychosocial care for people with diabetes: a position statement of the American Diabetes Association. *Diabetes care*. 2016;39(12):2126-40.
28. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche P, Devereaux P, et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ (Clinical research ed)*. 2010;340:c332.
29. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Annals of internal medicine*. 2013;158(3):200-7.
30. Markowitz JT, Butler DA, Volkening LK, Antisdel JE, Anderson BJ, Laffel LM. Brief screening tool for disordered eating in diabetes: internal consistency and external validity in a contemporary sample of pediatric patients with type 1 diabetes. *Diabetes care*. 2010;33(3):495-500.
31. Cherubini V, Skrami E, Iannilli A, Cesaretti A, Paparusso AM, Alessandrelli MC, et al. Disordered eating behaviors in adolescents with type 1 diabetes: A cross-sectional population-based study in Italy. *International Journal of Eating Disorders*. 2018;51(8):890-8.
32. Storch EA, Ledley DR. Peer victimization and psychosocial adjustment in children: Current knowledge and future directions. *Clinical Pediatrics*. 2005;44(1):29-38.
33. Gilbert P. *Compassion: Conceptualisations, research and use in psychotherapy*: Routledge; 2005.
34. Araia E, Hendrieckx C, Skinner T, Pouwer F, Speight J, King RM. Gender differences in disordered eating behaviors and body dissatisfaction among adolescents with type 1 diabetes: results from diabetes MILES youth—Australia. *International Journal of Eating Disorders*. 2017;50(10):1183-93.

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
35. Wisting L, Frøisland DH, Skrivarhaug T, Dahl-Jørgensen K, Rø Ø. Psychometric properties, norms, and factor structure of the Diabetes Eating Problem Survey–Revised in a large sample of children and adolescents with type 1 diabetes. *Diabetes Care*. 2013;36(8):2198-202.
36. Weinger K, Butler HA, Welch GW, La Greca AM. Measuring diabetes self-care: a psychometric analysis of the Self-Care Inventory-Revised with adults. *Diabetes care*. 2005;28(6):1346-52.
37. Khagram L, Martin CR, Davies MJ, Speight J. Psychometric validation of the Self-Care Inventory-Revised (SCI-R) in UK adults with type 2 diabetes using data from the AT. LANTUS Follow-on study. *Health and quality of life outcomes*. 2013;11(1):24.
38. Vaala SE, Hood KK, Laffel L, Kumah-Crystal YA, Lybarger CK, Mulvaney SA. Use of commonly available technologies for diabetes information and self-management among adolescents with type 1 diabetes and their parents: a web-based survey study. *Interactive journal of medical research*. 2015;4(4):e24.
39. Polonsky WH, Anderson BJ, Lohrer PA, Welch G, Jacobson AM, Aponte JE, et al. Assessment of diabetes-related distress. *Diabetes care*. 1995;18(6):754-60.
40. Schmitt A, Reimer A, Kulzer B, Haak T, Ehrmann D, Hermanns N. How to assess diabetes distress: comparison of the Problem Areas in Diabetes Scale (PAID) and the Diabetes Distress Scale (DDS). *Diabetic Medicine*. 2016;33(6):835-43.
41. Raes F, Pommier E, Neff KD, Van Gucht D. Construction and factorial validation of a short form of the self-compassion scale. *Clinical psychology & psychotherapy*. 2011;18(3):250-5.
42. Neff KD. The development and validation of a scale to measure self-compassion. *Self and identity*. 2003;2(3):223-50.
43. Neff KD, Rude SS, Kirkpatrick KL. An examination of self-compassion in relation to positive psychological functioning and personality traits. *Journal of research in personality*. 2007;41(4):908-16.
44. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. *Journal of health and social behavior*. 1983:385-96.
45. Surwit RS, Van Tilburg MA, Zucker N, McCaskill CC, Parekh P, Feinglos MN, et al. Stress management improves long-term glycemic control in type 2 diabetes. *Diabetes care*. 2002;25(1):30-4.
46. Lee E-H. Review of the psychometric evidence of the perceived stress scale. *Asian nursing research*. 2012;6(4):121-7.
47. Daneman D. Type 1 diabetes. *The Lancet*. 2006;367(9513):847-58.
48. Neff KD, McGehee P. Self-compassion and psychological resilience among adolescents and young adults. *Self and identity*. 2010;9(3):225-40.
49. Serlachius A, Northam E, Frydenberg E, Cameron F. Adapting a generic coping skills programme for adolescents with type 1 diabetes: a qualitative study. *Journal of health psychology*. 2012;17(3):313-23.

Figure 1: Flow of participants through the study







SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Page Number, on which item is reported
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	p.1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	p.2
	2b	All items from the World Health Organization Trial Registration Data Set	na
Protocol version	3	Date and version identifier	p.1
Funding	4	Sources and types of financial, material, and other support	p.17
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	p.1 & 17
	5b	Name and contact information for the trial sponsor	na
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	na
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	na

## Introduction



1				
2				
3				
4	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	p.4-6
5				
6				
7				
8				
9		6b	Explanation for choice of comparators	p.14
10	Objectives	7	Specific objectives or hypotheses	p.6
11				
12	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	p.7
13				
14				
15				
16				
17				
18				
19	<b>Methods: Participants, interventions, and outcomes</b>			
20				
21	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	p.7
22				
23				
24				
25				
26	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	p.7
27				
28				
29				
30				
31	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	p.8-9
32				
33				
34				
35				
36		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	p.14
37				
38				
39				
40				
41		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	na
42				
43				
44				
45		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	na
46				
47				
48	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	p.10-13
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1				
2				
3				
4	Participant	13	Time schedule of enrolment, interventions (including	
5	timeline		any run-ins and washouts), assessments, and visits for	p.21
6			participants. A schematic diagram is highly	
7			recommended (see Figure)	
8				
9	Sample size	14	Estimated number of participants needed to achieve	
10			study objectives and how it was determined, including	p.7
11			clinical and statistical assumptions supporting any	
12			sample size calculations	
13				
14	Recruitment	15	Strategies for achieving adequate participant	na
15			enrolment to reach target sample size	
16				

### Methods: Assignment of interventions (for controlled trials)

#### Allocation:

17				
18				
19				
20				
21	Sequence	16a	Method of generating the allocation sequence (eg,	
22	generation		computer-generated random numbers), and list of any	
23			factors for stratification. To reduce predictability of a	
24			random sequence, details of any planned restriction	p.10
25			(eg, blocking) should be provided in a separate	
26			document that is unavailable to those who enrol	
27			participants or assign interventions	
28				
29				
30	Allocation	16b	Mechanism of implementing the allocation sequence	
31	concealment		(eg, central telephone; sequentially numbered,	p.10
32	mechanism		opaque, sealed envelopes), describing any steps to	
33			conceal the sequence until interventions are assigned	
34				
35	Implementation	16c	Who will generate the allocation sequence, who will	p.10
36			enrol participants, and who will assign participants to	
37			interventions	
38				
39	Blinding	17a	Who will be blinded after assignment to interventions	
40	(masking)		(eg, trial participants, care providers, outcome	p. 10
41			assessors, data analysts), and how	
42				
43		17b	If blinded, circumstances under which unblinding is	
44			permissible, and procedure for revealing a	na
45			participant's allocated intervention during the trial	
46				
47				

### Methods: Data collection, management, and analysis

48				
49				
50	Data collection	18a	Plans for assessment and collection of outcome,	
51	methods		baseline, and other trial data, including any related	
52			processes to promote data quality (eg, duplicate	
53			measurements, training of assessors) and a description	p.10-13
54			of study instruments (eg, questionnaires, laboratory	
55			tests) along with their reliability and validity, if	
56			known. Reference to where data collection forms can	
57			be found, if not in the protocol	
58				
59				
60				

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	na
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	na
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	p. 13
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	p.13
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	p.13

### Methods: Monitoring

Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	na
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	na
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	p. 14
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	na

### Ethics and dissemination

1				
2				
3				
4	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	p.14
5				
6				
7				
8	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	p.7
9				
10				
11				
12				
13				
14	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	p.10
15				
16				
17				
18		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	na
19				
20				
21				
22	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	na
23				
24				
25				
26				
27				
28	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	p.16
29				
30				
31	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	na
32				
33				
34				
35	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	p.14
36				
37				
38				
39				
40	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	p.14
41				
42				
43				
44				
45				
46				
47		31b	Authorship eligibility guidelines and any intended use of professional writers	p.17
48				
49				
50		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	na
51				
52				
53				
54	<b>Appendices</b>			
55				
56	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	na
57				
58				
59				
60				

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Biological specimens

33 Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable

na

For peer review only